Published in Mol Psychiatry on January 01, 2002
Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A (2004) 2.36
Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther (2003) 1.57
Group II metabotropic glutamate receptors and schizophrenia. Cell Mol Life Sci (2009) 1.04
Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice. Neuropsychopharmacology (2011) 0.99
Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? Am J Psychiatry (2009) 0.98
Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.97
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann N Y Acad Sci (2014) 0.92
Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics. J Psychiatry Neurosci (2014) 0.92
Synapse-specific contributions in the cortical pathology of schizophrenia. Neurobiol Dis (2013) 0.91
Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys. Psychopharmacology (Berl) (2005) 0.89
Metabotropic glutamate receptor 2 and 3 gene expression in the human prefrontal cortex and mesencephalon in schizophrenia. Int J Neurosci (2008) 0.85
Serotonergic hallucinogens as translational models relevant to schizophrenia. Int J Neuropsychopharmacol (2013) 0.82
Group II metabotropic glutamate receptors modify N-methyl-D-aspartate receptors via Src kinase. Sci Rep (2013) 0.82
The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Curr Neuropharmacol (2014) 0.82
Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments. Biomol Ther (Seoul) (2012) 0.80
Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment. Trends Neurosci (2015) 0.80
Developmental expression of mGlu2 and mGlu3 in the mouse brain. Gene Expr Patterns (2016) 0.75
Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs. Front Pharmacol (2016) 0.75
Metabotropic glutamate receptor 3 (mGlu3; mGluR3; GRM3) in schizophrenia: Antibody characterisation and a semi-quantitative western blot study. Schizophr Res (2016) 0.75
Reduction of synapsin in the hippocampus of patients with bipolar disorder and schizophrenia. Mol Psychiatry (2002) 2.43
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) (2005) 2.37
Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry (2003) 2.18
Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Mol Psychiatry (2007) 2.12
Relative risk for cognitive impairments in siblings of patients with schizophrenia. Biol Psychiatry (2001) 2.08
Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry (1992) 2.07
Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. Am J Psychiatry (1993) 1.78
The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry (1993) 1.75
Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function. Neuroscience (2003) 1.74
Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry (1995) 1.71
Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Mol Psychiatry (2004) 1.62
ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J (2011) 1.61
Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology (1993) 1.58
Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch Gen Psychiatry (1993) 1.52
BDNF and trkB mRNA expression in the hippocampus and temporal cortex during the human lifespan. Gene Expr Patterns (2006) 1.48
Choline acetyltransferase in schizophrenia. Am J Psychiatry (1993) 1.47
Catechol-o-methyltransferase enzyme activity and protein expression in human prefrontal cortex across the postnatal lifespan. Cereb Cortex (2006) 1.46
Monoclonal antibodies to study the brain in schizophrenia. Brain Res (1989) 1.45
Neuregulin-1 (NRG-1) mRNA and protein in the adult human brain. Neuroscience (2004) 1.40
Localization of epidermal growth factor receptors and putative neuroblasts in human subependymal zone. J Comp Neurol (2000) 1.40
Basal ganglia iron in tardive dyskinesia: an MRI study. Biol Psychiatry (1994) 1.39
Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol Psychiatry (2005) 1.27
Presynaptic proteins in the prefrontal cortex of patients with schizophrenia and rats with abnormal prefrontal development. Mol Psychiatry (2003) 1.23
Postnatal alterations in dopaminergic markers in the human prefrontal cortex. Neuroscience (2006) 1.19
The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci (1991) 1.17
Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families. Rheumatology (Oxford) (2007) 1.17
Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science (1996) 1.13
SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. J Nucl Med (1994) 1.12
Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience (1999) 1.11
Cerebellar pathology in schizophrenia: a controlled postmortem study. Am J Psychiatry (1980) 1.11
A postmortem quantitative study of iron in the globus pallidus of schizophrenic patients. Biol Psychiatry (1990) 1.10
The hypothalamic leptin receptor in humans: identification of incidental sequence polymorphisms and absence of the db/db mouse and fa/fa rat mutations. Diabetes (1996) 1.09
Speaking, thinking, and blinking. Psychiatry Res (1981) 1.09
Transcriptional profiling in the human prefrontal cortex: evidence for two activational states associated with cocaine abuse. Pharmacogenomics J (2003) 1.09
Plasma prolactin concentrations and psychopathology in chronic schizophrenia. Arch Gen Psychiatry (1982) 1.08
Alterations in trkB mRNA in the human prefrontal cortex throughout the lifespan. Eur J Neurosci (2002) 1.08
Promoter specific alterations of brain-derived neurotrophic factor mRNA in schizophrenia. Neuroscience (2010) 1.05
Oestrogen receptor alpha localisation in the prefrontal cortex of three mammalian species. J Neuroendocrinol (2008) 1.04
Inflammatory neutrophils retain susceptibility to apoptosis mediated via the Fas death receptor. J Leukoc Biol (2000) 1.02
Cystic fibrosis transmembrane conductance regulator expression in human hypothalamus. Neuroreport (1998) 1.01
Reduced GSK-3beta mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients. J Neural Transm (Vienna) (2004) 1.01
Neuropathology of bipolar disorder. Biol Psychiatry (2000) 1.00
BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. Ann Rheum Dis (2007) 0.99
Persistent alterations in dendrites, spines, and dynorphinergic synapses in the nucleus accumbens shell of rats with neuroleptic-induced dyskinesias. J Neurosci (2000) 0.98
The hippocampus and parahippocampus in schizophrenia, suicide, and control brains. Arch Gen Psychiatry (1990) 0.98
Expression of estrogen receptor alpha exon-deleted mRNA variants in the human and non-human primate frontal cortex. Neuroscience (2005) 0.96
Is there cognitive decline in schizophrenia? A cross-sectional study. Br J Psychiatry (1994) 0.95
Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience (2005) 0.95
Drug effect on blink rates in rhesus monkeys: preliminary studies. Biol Psychiatry (1981) 0.95
A biologically important single nucleotide polymorphism within the toll-like receptor-4 gene is not associated with rheumatoid arthritis. Clin Exp Rheumatol (2003) 0.95
Synaptophysin and GAP-43 mRNA levels in the hippocampus of subjects with schizophrenia. Schizophr Res (2001) 0.95
The dopamine transporter and dopamine D2 receptor messenger RNAs are differentially expressed in limbic- and motor-related subpopulations of human mesencephalic neurons. Neuroscience (1994) 0.94
Postnatal development of tyrosine hydroxylase- and dopamine transporter-immunoreactive axons in monkey rostral entorhinal cortex. Cereb Cortex (1998) 0.93
Alterations of hippocampal secreted N-CAM in bipolar disorder and synaptophysin in schizophrenia. Mol Psychiatry (1999) 0.91
A quantitative immunohistochemical study of astrocytes in the entorhinal cortex in schizophrenia, bipolar disorder and major depression: absence of significant astrocytosis. Brain Res Bull (2001) 0.91
Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Am J Psychiatry (1997) 0.91
Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry (1991) 0.91
The entorhinal cortex: an examination of cyto- and myeloarchitectonic organization in humans. Cereb Cortex (1997) 0.91
A quantitative investigation of hippocampal pyramidal cell size, shape, and variability of orientation in schizophrenia. Arch Gen Psychiatry (1989) 0.90
Pharmacological and regional characterization of [3H]LY278584 binding sites in human brain. J Neurochem (1993) 0.89
Relative risk of neurological signs in siblings of patients with schizophrenia. Am J Psychiatry (2001) 0.89
Eye-blink rates and platelet monoamine oxidase activity in chronic schizophrenic patients. Biol Psychiatry (1980) 0.89
Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats. Synapse (1999) 0.88
Neuropathology of the cerebellum in schizophrenia--an update: 1996 and future directions. Biol Psychiatry (1997) 0.88
A 5' promoter region SNP in NRG1 is associated with schizophrenia risk and type III isoform expression. Mol Psychiatry (2009) 0.88
Serotonin and 5-hydroxyindoleacetic acid in brains of suicide victims. Comparison in chronic schizophrenic patients with suicide as cause of death. Arch Gen Psychiatry (1986) 0.88
Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry (1991) 0.88
A comparison of verbal fluency tasks in schizophrenic patients and normal controls. Schizophr Res (2001) 0.88
Quantitative magnetic resonance imaging in Rett syndrome. J Neuropsychiatry Clin Neurosci (1991) 0.87
Interaction of opioid peptides and other drugs with multiple kappa receptors in rat and human brain. Evidence for species differences. Peptides (1993) 0.87
Effects of area postrema/caudal medial nucleus of solitary tract lesions on food intake and body weight. Am J Physiol (1983) 0.87
Molecular signatures in post-mortem brain tissue of younger individuals at high risk for Alzheimer's disease as based on APOE genotype. Mol Psychiatry (2010) 0.87
Spontaneous asymmetric circling behavior in hemi-parkinsonism; a human equivalent of the lesioned-circling rodent behavior. Life Sci (1987) 0.87
Cerebral ventricular enlargement in chronic schizophrenia. An association with poor response to treatment. Arch Gen Psychiatry (1980) 0.86
Course of schizophrenia: neuropsychological evidence for a static encephalopathy. Schizophr Bull (1993) 0.86
A qualitative and quantitative analysis of the entorhinal cortex in schizophrenia. Cereb Cortex (1997) 0.86
Abnormal expression of cell recognition molecules in schizophrenia. Exp Neurol (1998) 0.85